Nautilus Biotechnology, Inc.
No SEC Form 4 filings for $NAUT in the last 30 days.
See all $NAUT insider activity →Nautilus Biotechnology reported 3Q 2026 revenue of $234K, up from $0 a year earlier, with a net loss of $15.64M and EPS loss of $0.12. Revenue came from research grants and services. The company plans 2027 pre-orders for its Voyager instrument and is adjusting assay development focus.
Nautilus Biotechnology reported Q3 progress in oncology assays, but net loss widened to $15.6M YoY. Cash reserves stood at $114.3M, with instrument availability still planned for mid-2027, according to the company.
Nautilus Biotechnology reported Q3 2026 revenue of $234,000 and a net loss of $15.6 million. Operating expenses were $16.9 million, with cash reserves at $114.3 million. The company highlighted progress in proteoform assays and its Voyager platform development, including a peer-reviewed paper in Nature Methods and participation in a multi-center research consortium.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning NAUT (Nautilus Biotechnology, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 4 bearish.
Recent NAUT coverage spans earnings, technology and corporate actions.
Earnings miss with widening loss likely pressures the stock.
The widened loss and modest cash raise concerns about near‑term profitability.
The micro‑cap reported a sizable loss versus modest revenue, likely pressuring the stock lower.
The grant provides significant non‑dilutive funding and validates Nautilus' technology, likely supporting near‑term share price upside.
The quarterly loss and minimal revenue suggest continued cash burn, likely pressuring the stock lower.
AlphAI scores every news story that mentions NAUT with an AI model for sentiment and relevance, and aggregates insider trades from Nautilus Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nautilus Biotechnology reported 3Q 2026 revenue of $234K, up from $0 a year earlier, with a net loss of $15.64M and EPS loss of $0.12. Revenue came from research grants and services. The company plans 2027 pre-orders for its Voyager instrument and is adjusting assay development focus.
1 min readNautilus Biotechnology reported Q3 progress in oncology assays, but net loss widened to $15.6M YoY. Cash reserves stood at $114.3M, with instrument availability still planned for mid-2027, according to the company.
1 min readNautilus Biotechnology reported Q3 2026 revenue of $234,000 and a net loss of $15.6 million. Operating expenses were $16.9 million, with cash reserves at $114.3 million. The company highlighted progress in proteoform assays and its Voyager platform development, including a peer-reviewed paper in Nature Methods and participation in a multi-center research consortium.
1 min readNautilus Biotechnology (NAUT) joins a $51.7M research consortium, SEEDS, to study proteins linked to Alzheimer's and cancer. The company's Voyager Platform will analyze proteoforms to develop early diagnostics and therapeutics. SEEDS, funded by ARPA-H, aims to address protein misfolding and aggregation, with Nautilus focusing on tau and EWS::FLI1 proteins.
2 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nautilus Biotechnology Reports Third Quarter 2026 Financial Results SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter
2 min readNautilus Biotechnology (NAUT) will report Q3'26 earnings on October 27. Analysts expect revenue of $206.25K and a loss of $0.14 per share. The announcement is scheduled for 9:30 AM ET.
1 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 11, 2026, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA), LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0
1 min readNautilus Data Technologies said its EcoCore Facility Cooling Distribution Unit was recognized by NVIDIA as NVIDIA-Validated AI Factory Infrastructure and listed on NVIDIA’s DSX Infrastructure Marketplace. The company cited testing results: over 4.1 MW (N-mode) and 3.2 MW (N+1), with 2°C ATD. The unit is water-source agnostic and available globally with 15-week delivery.
3 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
6 min readNautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. naut-20260617 0001808805 FALSE 0001808805 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min read
